AZD3759 - CAS# 1626387-80-1 Catalog No.:M6469-10 Smiles: CC1=NN=C2[C@@H](CC(=O)OC(C)(C)C)N=C(C3=C(SC(C)=C3C)N12)C1C=CC(Cl)=CC=1

Smiles: CC1=NN=C2[C@@H](CC(=O)OC(C)(C)C)N=C(C3=C(SC(C)=C3C)N12)C1C=CC(Cl)=CC=1

GSK343 was used at 10-50 µM final concentration in vitro and in cellular assays

is a potent and selective G9a and GLP histone lysine methyltransferase inhibitor with an IC50 ~0

Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitorDMAT

Robarge KD

AZD3759 - CAS# 1626387-80-1 Catalog No.:M6469-10 Smiles: CC1=NN=C2[C@@H](CC(=O)OC(C)(C)C)N=C(C3=C(SC(C)=C3C)N12)C1C=CC(Cl)=CC=1AZD3759, CAS No. 1626387 80 1, is also known as zorifertinib. It is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3759 binds to and inhibits the activity of EGFR as well as certain mutant forms of EGFR. This prevents EGFR mediated signaling, and may lead to both induction of cell death and inhibition of tumor growth in EGFR overexpressing cells. EGFR,